Lifeboat Foundation

A team of ingenious bioengineers at Arizona State University (ASU) has harnessed the power of childhood nostalgia, unveiling a creative solution to a long-standing challenge in DNA origami research.

They’ve successfully employed a LEGO robotics kit to build an affordable, highly effective gradient mixer for purifying self-assembling DNA origami nanostructures. This innovative breakthrough, detailed in a paper published one PLOS ONE, promises to revolutionize how scientists approach DNA origami synthesis.

The creation of DNA origami structures is an intricate process, requiring precise purification of nanostructures. Traditionally, this purification step involved rate-zone centrifugation, relying on a costly piece of equipment called a gradient mixer. However, the maverick minds at ASU have demonstrated that even the iconic plastic bricks of LEGO can be repurposed for scientific advancement.

Watch more interviews on the mystery of consciousness: https://t.ly/zGDTU

Consciousness is what we can know best and explain least. It is the inner subjective experience of what it feels like to see red or smell garlic or hear Beethoven. Consciousness has intrigued and baffled philosophers. To begin, we must define and describe consciousness. What to include in a complete definition and description of consciousness?

Continue reading “Russ Hurlburt — What is Consciousness?” »

Resistance to current cancer treatments is an important problem that arises through various mechanisms, but one that stands out involves an overexpression of several factors associated with DNA repair. To counteract this type of resistance, different drugs have been developed to affect one or more DNA repair pathways, therefore, to test different compounds of natural origin that have been shown to induce cell death in cancer cells is paramount. Since natural compounds target components of the DNA repair pathways, they have been shown to promote cancer cells to be resensitized to current treatments. For this and other reasons, natural compounds have aroused great curiosity and several research projects are being developed around the world to establish combined treatments between them and radio or chemotherapy. In this work, we summarize the effects of different natural compounds on the DNA repair mechanisms of cancer cells and emphasize their possible application to re-sensitize these cells.

Day by day we are exposed to chemical carcinogens in the environment, ultraviolet (UV) radiation, ionizing radiation, and also those substances produced in our body during cellular metabolism that attack and produce a variety of DNA injuries. Each lesion favors the development of alterations in DNA and chromosomes, which favors oncogenic transformation and tumor progression. In order to reduce the number of changes in the genome and its instability, cells have several pathways of response to damage and DNA repair proteins that eliminate these lesions. DNA adducts, such as those created by alkylating agents, can be cleaved and repaired by base excision repair (BER) or by nucleotide excision repair (NER), depending on whether it is necessary to remove only a nitrogenous base or a nucleotide. Also, O-6-methylguanine-DNA methyltransferase (MGMT), an alkyltransferase, eliminates alkylations.

Dr. Alfonso Sabater pulled up two photos of Antonio Vento Carvajal’s eyes. One showed cloudy scars covering both eyeballs. The other, taken after months of gene therapy given through eyedrops, revealed no scarring on either eye.

Antonio, who’s been legally blind for much of his 14 years, can see again.

The teen was born with dystrophic epidermolysis bullosa, a rare genetic condition that causes blisters all over his body and in his eyes. But his skin improved when he joined a clinical trial to test the world’s first topical gene therapy. That gave Sabater an idea: What if it could be adapted for Antonio’s eyes?

The first successful transplantation of a cryopreserved rat kidney has indicated that long-term storage of human organs for transplantation may be possible.

“The other thing we might find is actually this long flow, [this] drip of pharmaceuticals: caffeine, lidocaine, cocaine, amphetamine, antidepressants, birth control — this long slow drift of them from cities into the [ocean] is… starting to hit these animals,” Hird said.

Shark Week show delves into whether sharks off the coast of Florida are coming into contact with the huge quantities of cocaine that get dumped in these waters.

Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, in collaboration with researchers at the University of California Santa Barbara, today announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions.

A new publication, “Optogenetic control of the integrated stress response reveals proportional encoding and the stress memory landscape,” authored by company founders and featured on the cover of Cell Systems describes a technique that triggers the ISR virtually using light and demonstrates how the accumulation of stress over time shifts a cell’s reaction from adaptation to apoptosis (programmed cell death).

“In a very real way, our platform puts cells into a virtual reality, making them experience stress in the absence of physical stressors,” said Maxwell Wilson, Ph.D., a co-founder of Integrated Biosciences and Assistant Professor of Molecular, Cellular, and Developmental Biology at the University of California Santa Barbara.

University of Sheffield.

This is according to a press release by the institution published on Friday.

Traumatic brain injury (TBI) is increasingly a major cause of disability across the globe. The current methods of diagnosis are inadequate at classifying patients and prognosis. TBI is a diagnostic and therapeutic challenge. There is no Food and Drug Administration (FDA)-approved treatment for TBI yet. It took about 16 years of preclinical research to develop accurate and objective diagnostic measures for TBI. Two brain-specific protein biomarkers, namely, ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein, have been extensively characterized. Recently, the two biomarkers were approved by the FDA as the first blood-based biomarker, Brain Trauma Indicator™ (BTI™), via the Breakthrough Devices Program. This scoping review presents (i) TBI diagnosis challenges, (ii) the process behind the FDA approval of biomarkers, and (iii) known unknowns in TBI biomarker biology.